Method and system for determining whether copy number variation exists in sample genome, and compute

专利摘要:
Provided are a method for determining whether a copy number variation exists in a sample genome, a system applied to implement the method, and a computer-readable medium. The method for determining whether a copy number variation exists in a sample genome comprises the steps of: sequencing the sample genome to obtain a sequencing result formed by multiple sequencing sequences; comparing the sequencing result with a reference genome sequence, so as to determine the distribution of the sequencing sequences on the reference genome sequence; determining, based on the distribution of the sequencing sequences on the reference genome sequence, multiple breakthrough points on the reference genome sequence, wherein the numbers of the sequencing sequences on either side of each breakthrough point are significantly different; determining, based on the multiple breakthrough points, a detection window on the reference genome; determining, based on the sequencing sequences falling in the detection window, a first parameter; and determining, based on the difference between the first parameter and a predetermined threshold, whether a copy number variation exists in the sample genome with respect to the detection window.
公开号:AU2012366077A1
申请号:U2012366077
申请日:2012-01-20
公开日:2014-08-07
发明作者:Shengpei CHEN；Hui Jiang；Xiaoyu PAN；Xuyang YIN；Chunlei Zhang；Chunsheng Zhang；Xiuqing Zhang
申请人:BGI DIAGNOSIS CO Ltd；
IPC主号:C12Q1-68

专利说明:
METHOD AND SYSTEM FOR DETERMINING WHETHER COPY NUMBER VARIATION EXISTS IN SAMPLE GENOME, AND COMPUTER READABLE MEDIUM TECHNICAL FIELD 5 Embodiments of the present disclosure generally relate to a method of determining whether copy number variation presents in a genome sample, and a system and a computer readable medium thereof. BACKGROUND 10 In fields of scientific research and application, problems of analyzing a single cell, a plurality of cells, or a trace of nucleic acid sample usually come out, for example, Pre-implantation Genetic Diagnosis (PGD) and Pre-implantation Genetic Screening (PGS) in a field of assisted reproductive technology involve analysis with a single germ cell, a single blastomeric cell or an embryonic cell; a field of non-invasive prenatal 15 diagnosis technology involves problem of detecting a trace of fetal cells in maternal peripheral blood; Metagenomics involves analysis with a single or a trace of biological cell in environment; and disease or physical research involves analysis with a single cell in tissue or body fluid. However, currently the method of determining copy number variation still needs to be 20 improved. SUMMARY Embodiments of the present disclosure seek to solve at least one of the problems existing in prior art to at least some extent. 25 Embodiments of a first broad aspect of the present disclosure provide a method of determining whether copy number variation presents in a genome sample. According to embodiments of the present disclosure, the method may comprise following steps: sequencing the genome sample, to obtain a sequencing result consisting of a plurality of reads; aligning the sequencing result to a reference genome sequence, to determine a 30 distribution of the reads in the reference genome sequence; determining a plurality of breakpoints in the reference genome sequence based on the distribution of the reads in the reference genome sequence, wherein the number of reads has significance at both 1 sides of the breakpoints; determining a detection window in the reference genome based on the plurality of the breakpoints; determining a first parameter based on reads falling in the detection window; and determining whether the copy number variation presents in the genome sample against the detection window based on difference between the first 5 parameter and a preset threshold. By using the method of determining whether copy number variation presents in a genome sample according to embodiments of the present disclosure, whether copy number variation presents in a genome sample may be effectively determined, which is suitable for various copy number variations, included but not limited to aneuploidy of chromosome, deletion of chromosome, and addition, 10 micro-deletion and micro-repetition of chromosome fragments. Embodiments of a second broad aspect of the present disclosure provide a system for determining whether copy number variation presents in a genome sample. According to embodiments of the present disclosure, the system may comprise: a sequencing apparatus, configured to sequence the genome sample, to obtain a 15 sequencing result consisting of a plurality of reads; an analysis apparatus, connected to the sequencing apparatus, configured to determine whether copy number variation presents in the genome sample based on the sequencing result, wherein the analysis apparatus further comprises: an aligning unit, configured to align the sequencing result to a reference genome sequence, to determine a distribution of the reads in the reference 20 genome sequence; a breakpoint determining unit, connected to the aligning unit, configured to determine a plurality of breakpoints in the reference genome sequence, based on the distribution of the reads in the reference genome sequence, wherein the number of reads has significance at both sides of the breakpoints; a detection window determining unit, connected to the breakpoint determining unit, configured to determine a 25 detection window in the reference genome based on the plurality of the breakpoints; a parameter determining unit, connected to the detection window determining unit, configured to determine a first parameter based on reads falling in the detection window; and a determining unit, connected to the parameter determining unit, configured to determine whether the copy number variation presents in the genome sample against the 30 detection window based on difference between the first parameter and a preset threshold. By using the system for determining whether copy number variation presents in a genome sample according to embodiments of the present disclosure, the method of 2 determining whether copy number variation presents in a genome sample according to embodiments of the present disclosure may be effectively implemented, which is suitable for various copy number variations, included but not limited to aneuploidy of chromosome, deletion of chromosome, and addition, micro-deletion and micro-repetition of 5 chromosome fragments. Embodiments of a third broad aspect of the present disclosure provide a computer readable medium. According to embodiments of the present disclosure, the computer readable medium is configured to perform by a processer to determine whether copy number variation presents in a genome sample through following steps: aligning the 10 sequencing result to a reference genome sequence, to determine a distribution of the reads in the reference genome sequence; determining a plurality of breakpoints in the reference genome sequence based on the distribution of the reads in the reference genome sequence, wherein the number of reads has significance at both sides of the breakpoints; determining a detection window in the reference genome based on the 15 plurality of the breakpoints; determining a first parameter based on reads falling in the detection window; and determining whether the copy number variation presents in the genome sample against the detection window based on difference between the first parameter and a preset threshold. By virtue of the computer readable medium, the method of determining whether copy number variation presents in a genome sample 20 according to embodiments of the present disclosure may be effectively implemented, so as to effectively determine whether copy number variation presents in a genome sample, which is suitable for various copy number variations, included but not limited to aneuploidy of chromosome, deletion of chromosome, and addition, micro-deletion and micro-repetition of chromosome fragments. 25 Additional aspects and advantages of embodiments of present disclosure will be given in part in the following descriptions, become apparent in part from the following descriptions, or be learned from the practice of the embodiments of the present disclosure. 30 BRIEF DESCRIPTION OF THE DRAWINGS These and other aspects and advantages of embodiments of the present disclosure will become apparent and more readily appreciated from the following descriptions made 3 with reference the accompanying drawings, in which: Fig.1 is a flow chart showing a method of determining whether copy number variation presents in a genome sample according to an embodiment of the present disclosure; Fig.2 is a schematic diagram showing a system for whether copy number variation 5 presents in a genome sample according to an embodiment of the present disclosure; Fig.3 is a flow chart showing a method of determining whether copy number variation presents in a genome sample according to another embodiment of the present disclosure; Fig.4 is an image showing chromosome karyotype analysis of a sample S1 10 according to embodiments of the present disclosure, in which the left panel shows a result obtained by the method of detecting copy number variation according to an embodiment of the present disclosure with a single embryonic cell which has been subjected to a whole genome amplification, the right panel shows a result obtained by directly sequencing (without subjecting to the whole genome amplification firstly) with 15 DNA extracted from the same single embryonic cell; and Fig.5 an image showing chromosome karyotype analysis of a sample S2 according to embodiments of the present disclosure, in which the left panel shows a result obtained by the method of detecting copy number variation according to an embodiment of the present disclosure with a single embryonic cell which has been subjected to a whole 20 genome amplification, the right panel shows a result obtained by directly sequencing (without subjecting to the whole genome amplification firstly) with DNA extracted from the same single embryonic cell. DETAILED DESCRIPTION 25 Reference will be made in detail to embodiments of the present disclosure. The same or similar elements and the elements having same or similar functions are denoted by like reference numerals throughout the descriptions. The embodiments described herein with reference to drawings are explanatory, illustrative, and used to generally understand the present disclosure. The embodiments shall not be construed to limit the 30 present disclosure In addition, terms such as "first" and "second" are used herein for purposes of description and are not intended to indicate or imply relative importance or significance. 4 Thus, features defined with "first" or "second" may explicitly or implicitly include one or more of said feature. Furthermore, in descriptions of the present disclosure, unless otherwise specified, "a plurality of" refers to two or more. If not specified, in formula or signs used herein, the same alphabet represents a same meaning. 5 1. Method of determining whether copy number variation presents in a genome sample According to a first aspect of the present disclosure, there is provided a method of determining whether copy number variation presents in a genome sample in the present 10 disclosure. Term of "copy number variation (CNV)" used herein refers to abnormality of chromosome or chromosome fragment copy number, including but not limited to chromosome aneuploidy, chromosome fragment deletion, addition, micro-deletion and micro-repeat of chromosome fragment. Referring to Fig.1, the method of determining whether copy number variation 15 presents in a genome sample according to embodiments of the present disclosure comprises: S100: sequencing the genome sample, to obtain a sequencing result consisting of a plurality of reads According to embodiments of the present disclosure, types of the genome samples 20 with which the method of the present disclosure are not subjected to special restrictions, which may be a whole genome or a part of a genome, for example, chromosome or chromosome fragment. Besides, according to embodiments of the present disclosure, prior to the step of sequencing the genome sample, the method of determining whether copy number variation presents in a genome sample may further comprise a step of 25 extracting the genome sample from a biological sample. Accordingly, the biological sample may be directly used as raw material, for obtaining information regarding whether the biological sample has copy number variation, so as to reflect health status of organisms. According to embodiments of the present disclosure, the used biological sample is not subjected to special restrictions. According to some specific examples of 30 the present disclosure, the biological sample is any one selected from a group consisting of blood, urine, saliva, tissue, germ cells, oosperm, blastomere and embryo. It would be appreciated by those skilled in the art that different biological samples may be used for 5 analyzing different diseases. Accordingly, these samples may be conveniently obtained from organisms, and different samples may be used specifically directing to certain diseases, so as to selecting specific means for analyzing the certain diseases. For example, for a subject possibly suffering a certain cancer, a sample may be collected 5 from cancerous tissue or juxtacancerous tissue, from which cells are further isolated for analysis, accordingly, whether such tissue become cancerous may be accurately determined as early as possible. According a specific example of the present disclosure, a single cell may be used as the biological sample. According to embodiments of the present disclosure, methods and devices of isolating a single cell from a biological 10 sample are not subjected to special restrictions. According to some specific examples of the present disclosure, a single cell may be isolated from a biological sample using at least one of dilution, mouth-controlled pipette, micromanipulation (micro-dissection is preferred), flow cytometry isolation, microfluidics. Accordingly, a single cell may be effectively and conveniently obtained from a biological sample, to implement subsequent 15 steps. Then, efficiency of determining whether copy number variation presents in a genome sample may be further improved. Besides, according to embodiments of the present disclosure, methods of sequencing the genome sample are not subjected to special restrictions. According to an embodiment of the present disclosure, the step of sequencing the genome sample further 20 comprises following sub-steps of: firstly amplifying the genome sample, to obtain an amplified genome sample; secondly, constructing a sequencing-library with the amplified genome sample; finally sequencing the constructed sequencing-library, to obtain the sequencing result consisting of a plurality of reads. Accordingly, whole genome information of the sequencing result of the genome sample may be effectively obtained, 25 and a single cell genome or a trace of nucleic acid sample may be subjected to effective sequencing, which may further improve efficiency of determining whether copy number variation presents in a genome sample. Those skilled in the art may choose different methods of constructing a sequencing-library in accordance with specific solutions used in genome sequencing techniques. A detailed process of constructing a genome 30 sequencing-library may refer to a specification provided by sequencing-instrument manufacturer, such as Illumina Company, for example Multiplexing Sample Preparation Guide (Part#1 005063; Feb 2010), which is incorporated herein by reference. 6 Optionally, for the step of extracting the genome sample from the biological sample when being a single cell, according to embodiments of the present disclosure, the method may further comprise a step of lysing the single cell, to release whole genome of the single cell. According to some examples of the present disclosure, methods of lysing 5 the single cell to release whole genome are not subjected to special restrictions, as long as the single cell is lysed, preferably the single cell is fully lysed. According to specific examples of the present disclosure, the single cell is lysed using an alkaline lysate, to release whole genome of the single cell. Inventors of the present disclosure find out that the step of lysing the single cell may effectively lyse the single cell to release whole 10 genome, and accuracy may be improved when subjecting the released whole genome to sequencing, which may further improve efficiency of determining whether copy number variation presents in a genome sample. According to embodiments of the present disclosure, methods of amplifying a single cell whole genome are not subjected to special restrictions, a PCR-based method may be used, for example PEP-PCR, DOP-PCR and 15 OmniPlex WGA; a non-PCR-based method may be also used, for example Multiple Displacement Amplification (MDA). According to specific examples of the present disclosure, the PCR-based method is preferably used, for example OmniPlex WGA. A commercial kit, including but not limited to GenomePlex from Sigma Aldrich, PicoPlex from Rubicon Genomics, REPLI-g from Qiagen, illustra GenomiPhi from GE Healthcare 20 and etc, may be used. According to specific examples of the present disclosure, prior to the sub-step of constructing a sequencing-library, the single cell whole genome may be amplified by OmniPlex WGA. Accordingly, the whole genome may be effectively amplified, which may further improve efficiency of determining whether copy number variation presents in a genome sample. According to embodiments of the present disclosure, the 25 sub-step of sequencing the whole genome sequencing-library is performed by at least one selected from Next-Generation sequencing technology consisting of Hiseq system of Illumina Company, Miseq system of Illumina Company, Genome Analyzer (GA) system of Illumina Company, 454 FLX of Roche Company, SOLiD system of Applied Biosystems Company, Ion Torrent system of Life Technologie Company. Accordingly, characteristics 30 of high-throughput and deep sequencing of these sequencing apparatus may be used, which further improves efficiency of determining whether copy number variation presents in a genome sample. Obviously, it would be appreciated by those skilled in the art that 7 other sequencing methods and apparatuses may also be used for whole genome sequencing, for example Third-Generation sequencing technology (i.e., single molecule sequencing technology) such as any one of HeliScope system from Helicos BioSciences Company, RS system from PacBio Company and etc., as well as more advanced 5 sequencing technology which may be developed later. According to embodiments of the present disclosure, lengths of sequencing data obtained by whole genome sequencing are not subjected to special restrictions. According to a specific example of the present disclosure, the plurality of sequencing data have an average length of about 50 bp. The inventors of the present disclosure surprisingly find out that sequencing data having a 10 length of about 50 bp may greatly faciliate subjecting the sequencing data to analyzing, which improves analysis efficiency and significantly reduces cost for analysis, by which further improves efficiency of determining chromosome aneuploidy of a single cell and reduces cost of determining chromosome aneuploidy of a single cell. Term of "average length" used herein refers to a mean value of length values of every sequencing data. 15 S200: aligning the sequencing result to a reference genome sequence, to determine a distribution of the reads in the reference genome sequence After completing the step of sequencing the genome sample, the obtained sequencing result includes a plurality of sequencing data. The obtained sequencing result is aligned to a reference genome sequence, so as to determine a location of the 20 obtained sequencing result in the reference genome sequence. According to embodiments of the present disclosure, any known methods may be used to calculate the total number of these sequencing data. For example, software provided by sequencing instrument manufacturer may be used for analysis. Short Oligonucleotide Analysis Package (SOAP) and Burrows-Wheeler Aligner (BWA) are preferably used, 25 which align reads to a reference genome sequence, to obtain a location of reads in the reference sequence. A default parameter provided by program of the software may be used in alignment, or a parameter may be selected by those skilled in the art as required. In an embodiment of the present disclosure, SOAPaligner/soap2 is used as alignment software. 30 According to embodiments of the present disclosure, the reference genome sequence may be a standard human genome reference sequence in NCBI database (for example may be hg18, NCBI Build 36); or may be a part of a known genome sequence, 8 for example may be at least one sequence selected from a group consisting of human chromosome 21, chromosome 18, chromosome 13, chromosome X and chromosome Y. According to embodiments of the present disclosure, by the step of aligning the sequencing result to a reference genome sequence, sequences which are uniquely 5 aligned to the reference genome sequence may be selected for subsequent analysis. Accordingly, interference to analysis of copy number variation by repeat sequences may be avoided, which further improves efficiency of determining whether copy number variation presents in a genome sample. S300: determining a plurality of breakpoints in the reference genome 10 sequence based on the distribution of the reads in the reference genome sequence Term of "breakpoints" used herein refers to such kind of sites in a genome, in which the number of the reads on either side of the site are significantly different between these two regions. As reads derive from the genome sample, when a certain region presents copy number variation in the genome sample, the number of the reads corresponded in 15 the region also changes significantly. Accordingly, after determining a plurality of breakpoints, copy number variation probably presents in a region between two successive breakpoints may be preliminary determined. According to embodiments of the present disclosure, the step of determining a plurality of breakpoints in the reference genome sequence further comprises following 20 sub-steps: Firstly, the reference genome sequence is divided into a plurality of primary windows having a predetermined length, and reads falling in each of the plurality of primary windows are determined. According to specific examples of the present disclosure, by conventional alignment programs, reads contained in the obtained sequencing result 25 may be aligned to the reference genome sequence, by which reads falling in each of the plurality of primary windows may be determined, for example, it may be accomplished in the step S200 above-described. According to specific examples of the present disclosure, the reads falling in each of the plurality of primary windows are uniquely-aligned reads. Accordingly, interference to analysis of copy number variation by repeat sequences may 30 be avoided, which further improves efficiency of determining whether copy number variation presents in a genome sample. Secondly, for at least one site in the reference genome sequence, determining the 9 number of reads falling in the same number of the plurality of primary windows at both sides of the site. According to embodiments of the present disclosure, correlation analysis may be performed with all sites in the reference genome sequence, or with interested chromosome, for example such correlation analysis is performed with all sites 5 in at least one of human chromosome 21, chromosome 18, chromosome 13, chromosome X and chromosome Y. According to embodiments of the present disclosure, each of the primary windows may have same or different length; an overlap may present between primary windows, as long as information of each primary window is known; each of the primary windows is preferably has a same length. According to embodiments of the 10 present disclosure, each of plurality of the primary windows may have a length of 100 to 200 Kbp, preferably 150 Kbp. According to embodiments of the present disclosure, the number of the primary windows located at both sides of the site is not subjected to special restrictions, according to a specific example of the present disclosure, 100 of the primary windows may be selected from either side of the site respectively. 15 Thirdly, by statistical analysis, p value of the site may be determined, in which the p value represents that the number of reads falling in either side of the site has significance. If the p value of the site is smaller than a final p value, that the site is the breakpoints is determined. According to embodiments of the present disclosure, a range of the final p value may be determined by subjecting a known sequence sample to parallel analysis, 20 according to a specific example of the present disclosure, the final p value is 1.1 X 10-50. According to an embodiment of the present disclosure, the sub-step of determining p value of the site further comprises: For the selected site, primary windows having the same number at either side of the site are selected, the relative number of reads falling in each primary window Ri is 25 calculated, in which i represents the No. of the primary windows, the relative number of reads falling in all primary windows Ri are subjected to Run-Test, to determine the p value of the site, in which the relative number of reads is determined by following formula: .R log, 30 in which ri represents the number of reads falling in the i-th primary window, 10 na n represents the total number of the primary windows. In details, the step of subjecting all of the relative numbers of the reads falling in each of the plurality of primary windows to Run-Test further comprises: subjecting the 5 relative number of reads falling in each of the plurality of primary windows Ri to a correction of GC content, to obtain corrected relative number of reads i; determining the normalized number of reads falling in each of the plurality of primary windows Zi based on the corrected relative number of reads; and subjecting all of the normalized numbers of reads falling in each of the plurality of primary windows Zi to Run-Test. 10 More specifically, the corrected relative number of reads is obtained by following steps: Firstly GC content of each primary window is calculated; Secondly, the GC content is divided into a plurality of regions in accordance with a predetermined value, and a mean value Ms of the relative number of reads falling in each 15 of the plurality of regions is calculated, in which s is No. of the plurality of regions, according to embodiments of the present disclosure, the predetermined value may be any numerical value in a range of 0.0005 to 0.01, of which a corresponding region has a length of 50 k to 300 k, 0.001 is preferred, by which may performing a correlation with an optimal power. 20 Thirdly, the corrected relative number of reads £ is determined based on the R =R, -3,1 following formula: Lastly, the normalized number of reads Zi is determined based on the following formula, in which Z =R - - mean )|SD) P1 = an1 25 - n 17 Accordingly, the number of reads may be subjected to correlation by GC content. 11 Thus, an interference caused by bias of genome amplification may be eliminated, by which improves accuracy and efficiency of determining whether copy number variation presents in a genome sample. After the plurality of breakpoints has been determined, a possibility that copy number 5 variation presents in a region between two successive breakpoints may be preliminary determined. Accordingly such regions may be taken as the detection windows for further determining whether copy number variation presents. In the case of obtaining relative more breakpoints in the preliminary determination, the obtained breakpoints may be subjected to further screening. Accordingly, according to embodiments of the present 10 disclosure, the step of determining a detection window in the reference genome based on the plurality of the breakpoints further comprises: 1) determining a plurality of candidate breakpoints, wherein other breakpoints present both before and after the candidate breakpoints; 2) determining p value of each candidate breakpoint, and removing a candidate 15 breakpoint having the maximal p value; 3) performing the step 2) with rest of the candidate breakpoints until all p values of the rest of the candidate breakpoints are smaller than the final p value, wherein the rest of the candidate breakpoints are taken as screened candidate breakpoints; and 4) determining a region between two successive screened candidate breakpoints as 20 the detection window. According to embodiments of the present disclosure, the p value of the candidate breakpoint is obtained by following steps: selecting a region between the candidate breakpoint and previous candidate breakpoint as a first candidate region, and selecting a region between the candidate 25 breakpoint and next candidate breakpoint as a second candidate region; subjecting the normalized number of reads falling in the primary windows Zi which are included both in the first candidate region and the second candidate region to Run-Test (The Run-Test is a nonparametric test, evaluating significant difference between two populations using evenly distributed status of mixed elements with two 30 populations. Details regarding such test may refer to Wald A. WJ. On a Test Whether Two Samples are from the Same Population. The Annals of Mathematical Statistics 1940; 11:147-162, which is incorporated herein by reference), to determine the p value of the 12 candidate breakpoints. According to embodiments of the present disclosure, the final p value is obtained by following steps: based on a sequencing result of a control sample, repeating the step of determining 5 a detection window in the reference genome, and recording p values of the breakpoints which are removed each time until the number of the breakpoints is zero, in which term of "control sample" used herein refers to a sample of which copy number variation does not present in a known nucleotide sequence; and based on a distribution of the p values of removed breakpoints, the final p value is 10 determined, for example, a distribution diagram is plotted with the p values of removed breakpoints, a p value having a maximal changing trend is taken as the final p value ( p ) According to specific examples of the present disclosure, the final p value is 1.1 X 104 . 15 S400: determining a first parameter based on reads falling in the detection window After the detection windows have been determined, reads contained in the detection windows may be subjected to statistical analysis, so as to determine whether copy number variation presents in the detection windows. According to an embodiments of the 20 present disclosure, the step of determining the first parameter based on reads falling in the detection windows further comprises: determining a mean value among all of the normalized numbers of reads falling in each of the plurality of primary windows Z which are included in the detection windows, in which the mean value of the normalized number of reads Z is taken as the first parameter. The normalized number of reads has been 25 specifically described above, which is omitted herein for brevity. S500: determining whether the copy number variation presents in the genome sample against the detection window based on difference between the first parameter and a preset threshold According to embodiments of the present disclosure, the determined first parameter 30 may be compared with a preset threshold, then based on difference between the first parameter and the present threshold, whether the copy number variation presents in the 13 genome sample is determined regarding the specific detection window. Based on the sequencing result of the genome sample, the number of reads falling in a certain window is positively related to content of the certain window in chromosome or genome, accordingly by subjecting reads deriving from a certain window in the sequencing result 5 to statistical analysis, whether the copy number variation presents in the genome sample may be effectively determined based on the certain window. Term of "preset threshold" used herein refers to relative parameter based on the certain window obtained by repeating the operations and analysis in the above embodiments using a normal genome sample having a known sequence. It would be appreciated that, relative parameter based 10 on the certain window and relative parameter of normal cells may be obtained by same sequencing conditions and mathematics methods. Here, the relative parameter of normal cells may be used as the preset threshold. Besides, term "preset" used herein should be broadly understood, which may be predetermined by experiment, or may be obtained by parallel experiments when analyzing the biological sample. Term "parallel experiment" 15 should be broadly understood, which may refer to sequencing and analyzing unknown and known samples at the same time, or may refer to performing the steps of sequencing and analyzing under same conditions successively. According to embodiments of the present disclosure, the preset threshold comprises a first threshold and a second threshold, by comparing the first parameter Z to the first threshold and the second 20 threshold, in the case of the first parameter Z smaller than the first threshold, copy number reducing is determined (i.e., deletion), in the case of the first parameter Z greater than the second threshold, copy number increasing is determined (i.e., addition), accordingly which type of the copy number variation may be determined. According to specific examples of the present disclosure, a = 0.05 is set as a boundary of significance, 25 by which type of the copy number variation is further determined. By the method of determining whether copy number variation presents in a genome sample according to embodiments of the present disclosure, whether copy number variation in the genome sample may be effectively determined, which is suitable for various variations, including but not limited to chromosome aneuploidy, chromosome 30 fragment deletion, fragment addition, addition, micro-deletion and micro-repeat of 14 chromosome fragment. Copy number variation is the major factor inducing birth defect, which is also very common in embryo cultured in vitro, being a major reason leading to failure of reproduction in vitro. Copy number variation is also a pathogenic factor to many diseases such as cancer. The whole genome amplification is technique which can 5 perform amplification in a range of whole genome with a single cell, a plurality cells or a trace of nucleic acid sample, which may increase sample amount on the premise of maintaining representativeness of the whole genome, to achieve the required sample amount. However, in general, a problem of amplification bias presents in the whole genome amplification, which brings in deviation to subsequent analysis. The method of 10 determining whether copy number variation presents in a genome sample according to embodiments of the present disclosure, after the single cell or a trace of nucleic acid sample has been subjected to whole genome amplification, data is obtained by sequencing technology for analysis of copy number variation. On one hand, a problem of having difficulties in analyzing with a single cell or a trace of nucleic acid sample is solved 15 by the whole genome amplification, on the other hand, bias to analyzing copy number variation induced by the whole genome amplification is avoided, which makes detection more accurate and more comprehensive, particularly detection efficiency may be further improved by a correlation of GC content. Besides, according to embodiments, during the sub-step of constructing sequencing-library with different samples, different indexes are 20 introduced, by which a plurality samples may be subjected to test at the same time, which further improves efficiency of determining whether copy number variation presents in a genome sample. Using the method of determining whether copy number variation presents in a genome sample according to embodiments of the present disclosure, screening and diagnosing copy number variation prior to embryo implantation or 25 noninvasive screening of fetal copy number variation may be determined, which is benefit to provide genetic counseling and basis for clinic decision; prenatal diagnosis may effectively prevent implantation of embryo with lesion, to present newborns with defects. 11 System for determining whether copy number variation presents in a genome 30 sample According to a second aspect of the present disclosure, there is provided a system for determining whether copy number variation presents in a genome sample. Using the 15 system may effectively implement the method of determining whether copy number variation presents in a genome sample above-described, so as to effectively determine whether copy number variation presents in the genome sample. Referring to Fig.2, according to embodiments of the present disclosure, the system 5 1000 for determining whether copy number variation presents in a genome sample comprises: a sequencing apparatus 100 and an analysis apparatus 200. According to embodiments of the present disclosure, the sequencing apparatus 100 is configured to sequence the genome sample, to obtain a sequencing result consisting of a plurality of reads. According to embodiments of the present disclosure, the system 10 1000 for determining whether copy number variation presents in a genome sample may further comprise a genome extracting apparatus (not shown in Figs). The genome extracting apparatus is configured to extract the genome sample from a biological sample, and the genome extracting apparatus is connected to the sequencing apparatus 100 for providing the genome sample. Accordingly, the biological sample may be directly used as 15 raw material, to obtain information whether copy number variation presents in the biological sample, so as to reflect health status of organisms. According to embodiments of the present disclosure, the sequencing apparatus 100 may further comprise: a genome amplifying unit, a sequencing-library constructing unit and a sequencing unit, in which the genome amplifying unit is configured to amplify the genome sample; the 20 sequencing-library constructing unit, connected to the genome amplifying unit, is configured to construct a sequencing-library with the amplified genome sample; and the sequencing unit, connected to the sequencing-library constructing unit, is configured to sequence the sequencing-library. According to embodiments of the present disclosure, the sub-step of sequencing the whole genome sequencing-library is performed by at 25 least one selected from Next-Generation sequencing technology (such as Hiseq system of Illumina Company, Miseq system of Illumina Company, Genome Analyzer (GA) system of Illumina Company, 454 FLX of Roche Company, SOLiD system of Applied Biosystems Company, Ion Torrent system of Life Technologie Company) and single molecule sequencing apparatus. Accordingly, characteristics of high-throughput and deep 30 sequencing of these sequencing apparatus may be used, which further improves efficiency of determining whether copy number variation presents in a genome sample. According to embodiments of the present disclosure, the analysis apparatus 200 is 16 connected to the sequencing apparatus 100, to determine whether copy number variation presents in a genome sample based on the sequencing result. According to embodiments of the present disclosure, the analysis apparatus 200 further comprises: an aligning unit 201, a breakpoint determining unit 202, a detection window determining unit 5 203, a parameter determining unit 204 and a determining unit 205, in which the aligning unit 201 is configured to align the sequencing result to a reference genome sequence, to determine a distribution of the reads in the reference genome sequence. According to embodiments of the present disclosure, a known human genome sequence is preserved in the aligning unit 201 as the reference genome sequence, optionally, the reference 10 genome sequence is at least one selected from human chromosome 21, chromosome 18, chromosome 13, chromosome X and chromosome Y. The breakpoint determining unit 202, connected to the aligning unit 201, is configured to determine a plurality of breakpoints in the reference genome sequence, based on the distribution of the reads in the reference genome sequence, as described above, the number of reads has 15 significance between two sides of the breakpoints. The detection window determining unit 203, connected to the breakpoint determining unit 202, is configured to determine a detection window in the reference genome based on the plurality of the breakpoints. The parameter determining unit 204, connected to the detection window determining unit, is configured to determine a first parameter based on reads falling in the detection window. 20 The determining unit 205, connected to the parameter determining unit 204, configured to determine whether the copy number variation presents in the genome sample against the detection window based on difference between the first parameter and a preset threshold. According to embodiments, the breakpoint determining unit 202 further comprises a 25 module for performing following sub-steps: dividing the reference genome sequence into a plurality of primary windows having a predetermined length, and determining reads falling in each of the plurality of the primary windows; Firstly, the reference genome sequence is divided into a plurality of primary windows 30 having a predetermined length, and reads falling in each of the plurality of primary windows are determined. According to specific examples of the present disclosure, by conventional alignment programs, reads contained in the obtained sequencing result 17 may be aligned to the reference genome sequence, by which reads falling in each of the plurality of primary windows may be determined. According to embodiments of the present disclosure, each of the primary windows may have same or different length; an overlap may present between primary windows, as long as information of each primary 5 window is known; each of the primary windows is preferably has a same length. According to embodiments of the present disclosure, each of the plurality of primary windows may have a length of 100 to 200 Kbp, preferably 150 Kbp. According to embodiments of the present disclosure, the number of the primary windows located at both sides of the site is not subjected to special restrictions, according to a specific 10 example of the present disclosure, 100 of the primary windows may be selected from either side of the site respectively. Secondly, p value of the site is determined; such p value may reflect significant difference of the number of reads between two sides of the site. Besides, the p value of the site is smaller than a final p value, the site is determined as the breakpoints. 15 According to embodiments of the present disclosure, a range of the final p value may be determined by subjecting a known sequence sample to parallel analysis, according to a specific example of the present disclosure, the final p value is 1.1 X 10 . According to embodiments of the present disclosure, the breakpoint determining unit 202 further comprises a module for performing following sub-steps: 20 For the selected site, the same number of the primary windows at either side of the site is selected respectively, and the relative number of reads falling in every primary window Ri is calculated, in which i represents No. of the primary windows, the relative number of reads falling in all primary windows Ri is subjected to Run-Test, o determine the p value of the site, in which 25 the relative number of reads is determined by following formula: R. 0 in which ri represents the number of reads falling in the i-th primary window, IF =Yr, n represents the total number of the primary windows. 30 According to embodiments of the present disclosure, the breakpoint determining unit 18 202 further comprises a module for performing followings to subject all of the relative numbers of the reads falling in each of the plurality of primary windows to Run-Test: subjecting the relative number of reads falling in each of the plurality of primary windows Ri to a correction of GC content, to obtain corrected relative number of reads 5 determining the normalized number of reads falling in each of the plurality of primary windows Zi based on the corrected relative number of reads; and subjecting all of the normalized number of reads falling in each of the plurality of primary windows Zi to Run-Test. 10 According to embodiments of the present disclosure, the corrected relative number of reads is obtained by a module for performing following steps: calculating GC content of each of the plurality of primary windows; dividing the GC content into a plurality of regions in a unit of 0.001, and calculating a mean value Ms among all of the relative numbers of reads falling in each of the plurality of 15 regions, wherein s is No. of the plurality of regions; determining the corrected relative number of reads i based on the following formula: h = -Mi determining the normalized number of reads Zi based on the following formula: 20 wherein Z(={R -, -mean )/SDwherein mean - - (Ri - R 1 After the plurality of breakpoints has been determined, a possibility that copy number 25 variation presents in a region between two successive breakpoints may be preliminary determined. Accordingly such regions may be taken as the detection windows for further determining whether copy number variation presents. In the case of obtaining relative more breakpoints in the preliminary determination, the obtained breakpoints may be 19 subjected to further screening. According to embodiments of the present disclosure, based on the plurality of the breakpoints, the detection window determining unit further comprises a module for performing followings: 1) determining a plurality of candidate breakpoints, wherein other breakpoints 5 present both before and after the candidate breakpoints; 2) determining p value of each candidate breakpoint, and removing a candidate breakpoint having the maximal p value; 3) performing the step 2) with rest of the candidate breakpoints until p values of the rest of the candidate breakpoints all smaller than the final p value, wherein the rest of the 10 candidate breakpoints are taken as screened candidate breakpoints; and 4) determining a region between two successive screened candidate breakpoints as the detection window. In which, according to embodiments of the present disclosure, the p value of the candidate breakpoint is obtained by following steps: 15 selecting a region between the candidate breakpoint and previous candidate breakpoint as a first candidate region, and selecting a region between the candidate breakpoint and next candidate breakpoint as a second candidate region; subjecting the normalized number of reads falling in the primary windows Zi which are included both in the first candidate region and the second candidate region to 20 Run-Test, to determine the p value of the candidate breakpoints. According to embodiments of the present disclosure, the final p value is obtained by following steps: based on a sequencing result of a control sample, repeating the step of determining a detection window in the reference genome, and recording p values of the breakpoints 25 which are removed each time until the number of the breakpoints is zero; and determining the final p value, based on a distribution of the p values of removed breakpoints, for example, a distribution diagram is plotted with the p values of removed breakpoints, a p value having a maximal changing trend is taken as the final p value ( p ).Y 30 According to specific examples of the present disclosure, the final p value is 1.1 X 104 . According to embodiments of the present disclosure, the parameter determining unit 20 204 further comprises a module for performing followings: determining a mean value among all of the normalized numbers of reads falling in each of the plurality of primary windows Z which are included in the detection windows, in which the mean value of the normalized number of reads Z is taken as the first parameter. Furthermore, a preset 5 threshold is preserved in the determining unit 205, accordingly, the determining unit 205 may compare the first parameter determined in the parameter determining unit 204, so as to determine whether copy number variation presents in the obtained detection windows, in which according to embodiments of the present disclosure, the preset threshold comprises: a first threshold and a second threshold, by comparing the first parameter Z 10 to the first threshold and the second threshold, in the case of the first parameter Z smaller than the first threshold, copy number reducing is determined (i.e., deletion), in the case of the first parameter Z greater than the second threshold, copy number increasing is determined (i.e., addition), accordingly which type of the copy number variation may be determined. According to specific examples of the present disclosure, a 15 = 0.05 is set as a boundary of significance, by which type of the copy number variation is further determined. Accordingly, using the system for determining whether copy number variation presents in a genome sample according to embodiments of the present disclosure, the method of determining whether copy number variation presents in a genome sample 20 according to embodiments of the present disclosure may be effectively implemented, so as to effectively determine whether copy number variation presents in the genome sample, which is suitable for various copy number variations, included but not limited to aneuploidy of chromosome, deletion of chromosome, and addition, micro-deletion and micro-repetition of chromosome fragments. 25 It should note that, it would be appreciated by those skilled in the art that, the above-described characteristics and advantages of the method of determining whether copy number variation presents in a genome sample is also suitable to the system for whether copy number variation presents in a genome sample, which are omitted for convenience and brevity. 30 21 Ill. Computer readable medium According to a third aspect of the present disclosure, there is provided a computer readable medium. According to embodiments of the present disclosure, an order is preserved in the computer readable medium, the order is configured to perform by a 5 processer to determine whether copy number variation presents in a genome sample through following steps: aligning the sequencing result to a reference genome sequence, to determine a distribution of the reads in the reference genome sequence; determining a plurality of breakpoints in the reference genome sequence based on the distribution of the reads in the reference genome sequence, wherein the number of reads has 10 significance at both sides of the breakpoints; determining a detection window in the reference genome based on the plurality of the breakpoints; determining a first parameter based on reads falling in the detection window; and determining whether the copy number variation presents in the genome sample against the detection window based on difference between the first parameter and a preset threshold. Using the computer 15 readable medium, the method of determining whether copy number variation presents in a genome sample according to embodiments of the present disclosure may be effectively implemented, so as to effectively determine whether copy number variation presents in the genome sample, which is suitable for various copy number variations, included but not limited to aneuploidy of chromosome, deletion of chromosome, and addition, 20 micro-deletion and micro-repetition of chromosome fragments. It should note that, it would be appreciated by those skilled in the art that, the above-described characteristics and advantages of the method of determining whether copy number variation presents in a genome sample is also suitable to the computer readable medium, which are omitted for convenience and brevity. 25 Reference will be made in detail to examples of the present disclosure. It would be appreciated by those skilled in the art that the following examples are explanatory, and cannot be construed to limit the scope of the present disclosure. If the specific technology or conditions are not specified in the examples, a step will be performed in accordance with the techniques or conditions described in the literature in the art (for example, 30 referring to J. Sambrook, et al. (translated by Huang PT), Molecular Cloning: A Laboratory Manual, 3rd Ed., Science Press) or in accordance with the product instructions. If the manufacturers of reagents or instruments are not specified, the 22 reagents or instruments may be commercially available, for example, from Illumina. General Method Referring to Fig.3, the method of determining whether copy number variation 5 presents in a genome sample used in examples comprises: Firstly, a whole genome sample is subjected to amplification, and then the amplified whole genome is sequenced to obtain reads (sequencing data); Secondly, the obtained reads are aligned to a standard human genome reference sequence in NCBI database by SOAP2, to obtain location information of the reads in the 10 genome. To avoid interference to analysis of copy number variation by repeat sequence, reads which are uniquely aligned to the human genome reference sequence are only selected for subsequent analysis. Thirdly, a site of which the number of reads falling in two sides respectively having a statistical significance is found, which comprises following steps: 15 a) calculating the relative number of reads of the testing sample(a plurality of samples may be analyzed at the same time): a window having a length of w is selected in the human genome reference sequence (w may be any integer greater than 1, for example 10 K to 10 M bp, 50 K to 1 M bp is preferred, 100 K to 300 K bp is more preferred, such as 150 K bp), the number of reads 20 falling in each window , is calculated in al obtained reads, in which subscript i represents No. of the windows, subscript j represents No. of the samples, GC content of each window GC is also calculated, then the relative number of reads is calculated by R =log 2 Ili r , in which the average number of reads is F 1 i=1 b) data correlation and normalization 25 in a coordinate system taking GC content as X-coordinate and the relative number of reads R as Y-coordinate, the X-coordinate is divided into a plurality of regions having same units, a mean value Ms of R in every region is calculated, s is No. of GC region; for every window of the sample, the corrected relative number of reads is calculated by R = R M;, GC content of window is in the s-th GC region; 23 for every window of the sample, the normalized relative number of reads z is calculated by , Z , = (R , -N, -meanSDj , inwhichmean YIR .N., SD=j (Ri N mean ) 5 n -1 c) determining and screening breakpoints determining breakpoints: for each site in the reference genome sequence, n windows (for example 100 windows) are selceted respectively from two sides of the site as two polulations for statistical test, one p value corresponding to each site is obtained by 10 calculating difference betweent two sides of the site, m sites (such as 3000 sites) having the minimum p value as breakpoint B, = {b, b 2 ,..., b, } screening breakpoints: all arranged breakpoints are recorded as each breakpoint preasents between two successive fragments, in which such two fragments are regions respective from a previous breakpoint to said breakpoint and from 15 said breakpoint to the a next breakpoint, all zu in such two fragments are subjected to statistical test (such as subjected to Run-Test, which is a nonparametric test, evaluating significant difference between two populations using evenly distributed status of mixed elements with two population). The obtained p value (Pk) is regarded as "bk is taken as significance of breakpoint". A candidate breakpoint having the maximum p value Pk is 20 removed, which are repeated until all p value smaller than a final p value PfiI of such chromosome; obtaining the final p value: during detection, the above step of determining a plurality 24 breakpoint is performed with a control sample as the testing sample, all arrange candidate breakpoints in whole genome are recorded as B=b,b 2 ,...,b, each candidate breakpoint bk preasents between two successive fragments, all zij in such two fragments are subjected to statistical test, the obtained p value (Pk) is regarded as "bk is 5 taken as significance of breakpoint". A candidate breakpoint having the least significance p value Pk is removed, which are repeated until the number of the candicate breakpoints is zero. A distribution diagram is plotted with the removed candidate breakpoint, a p value having a maximal changing trend is taken as the final p value (I'i-1); determining a detection window and verifying the detection window: after the 10 screened breakpoints have been obtained, the detection window is determined. To further determining the detection window, a mean value of Zij in such fragment is calculated, which is recored as Z. If Z exceeds a threshold, then copy number variation is determined presenting in such fragment, in which the threshold is determined as followings: 15 for each fragment after window combination, a mean value and a standard error of the normalization number of reads Zij in such fragment of all control samples are calculated. As Z in each frament fits normal distribution, a range of threshold of such fragment when a cumulative probalility is 0.05 is calculated according to the calculated mean value and standard error obtained in above steps, in which the range of threshold 20 is used as the threshold filtering whether copy number variation presents in the fragment. Example 1 Copy number variation dection of fetal fragments with an embryo single cell sample, and chromosome aneuploid detection with an embryo single cell sample 25 1. whole genome amplification: GenomePlex* Single Cell Whole Genome Amplification Kit from Sigma Aldrich Company was used in whole genome amplification with the two embryo single cell samples in the current example. The embryo single cell sample was trophoblast cell of the fifth day blastocysts, which was isolated from blastaea 5 by a laser capture microdissection method. After the two embryo single cell samples were lysed, the whole genome amplification was performed in accordance with instructions for kit provided by manufacturer. 2. sequencing: in the current example, Hiseq2000 sequencing platform from Illumina Company was used in sequencing the amplified whole genome DNA from the two 10 embryo single cell sample. According to instructions provided by Illumina Company, sequencing-library construction and sequencing on computer were performed, by which generated about 0.36 G data volume of each sample, distinguished by different index sequences. Using alignment software SOAP2, the reads obtained by sequencing were aligned to human genome reference sequencing in NCBI database, Build 36, to locate 15 the obtained reads in the human genome reference sequence. 3. Data analysis a) calculating the relative number of reads of a testingsample and a control sample (the control sample refered to a sample had normal karyotype) The human genome reference sequence was divided into a plurality of windows 20 having a length of 150K bp. The number of the reads obtained in step 2) falling in each window ', was calculated, in which the subscript i represented No. of the plurality of windows, j represented No. of samples. GC content was also calculated for each window. The relative number of reads was calculated in accordance with the formula given in 26 General Method. b) data correction and normalization in a coordinate system taking GC content as X-coordinate and the relative number of reads R as Y-coordinate, the X-coordinate is divided into a plurality of regions having 5 same units, in which the unit is 0.001. A mean value Ms of R in every region was calculated, s was No. of GC region, which were shown in Table.1. The obtained reads were subjected to correction and normalization in accordance to the formula given in General Method. M Table.1 List of s in each GC content region during correction Sample S1 Sample S2 Sample S1 Sample S2 s GC Ms GC Ms S GC M, GC M, 1 0.255-0.256 2.45 0.255-0.256 2.74 118 0.433-0.434 -0.23 0.452-0.453 -0.06 2 0.314-0.315 0.04 0.336-0.337 -0.26 119 0.434-0.435 -0.21 0.453-0.454 -0.15 3 0.317~0.318 0.22 0.337~0.338 -0.21 120 0.435-0.436 -0.25 0.454-0.455 -0.22 4 0.319-0.32 0.01 0.338-0.339 -0.18 121 0.436-0.437 -0.25 0.455-0.456 -0.16 5 0.32-0.321 0.19 0.339-0.34 0.16 122 0.437~0.438 -0.24 0.456-0.457 -0.19 6 0.321-0.322 0.13 0.34-0.341 -0.73 123 0.438-0.439 -0.23 0.457~0.458 -0.14 7 0.322-0.323 0.11 0.341-0.342 -0.3 124 0.439-0.44 -0.29 0.458-0.459 -0.15 8 0.323-0.324 0.12 0.342-0.343 -0.28 125 0.44-0.441 -0.28 0.459-0.46 -0.21 9 0.324-0.325 -0.08 0.343-0.344 -0.36 126 0.441-0.442 -0.41 0.46-0.461 -0.1 10 0.325-0.326 0.02 0.344-0.345 -0.31 127 0.442-0.443 -0.28 0.461-0.462 -0.2 11 0.326-0.327 0.39 0.345-0.346 -0.19 128 0.443-0.444 -0.36 0.462-0.463 -0.19 12 0.327~0.328 0.15 0.346-0.347 -0.18 129 0.444-0.445 -0.33 0.463-0.464 -0.12 13 0.328-0.329 0.11 0.347~0.348 -0.25 130 0.445-0.446 -0.35 0.464-0.465 -0.3 14 0.329-0.33 0.22 0.348-0.349 -0.33 131 0.446-0.447 -0.36 0.465-0.466 -0.29 15 0.33-0.331 0 0.349-0.35 -0.28 132 0.447~0.448 -0.3 0.466-0.467 -0.18 16 0.331-0.332 -0.04 0.35-0.351 -0.33 133 0.448-0.449 -0.47 0.467~0.468 -0.27 17 0.332-0.333 0.12 0.351-0.352 -0.14 134 0.449-0.45 -0.38 0.468-0.469 -0.24 18 0.333-0.334 0.12 0.352-0.353 -0.24 135 0.45-0.451 -0.43 0.469-0.47 -0.28 19 0.334-0.335 0.06 0.353-0.354 -0.23 136 0.451-0.452 -0.4 0.47~0.471 -0.25 27 20 0.335-0.336 0.14 0.354-0.355 -0.15 137 0.452-0.453 -0.34 0.471-0.472 -0.24 21 0.336-0.337 0.1 0.355-0.356 -0.21 138 0.453-0.454 -0.5 0.472-0.473 -0.44 22 0.337~0.338 0.08 0.356-0.357 -0.19 139 0.454-0.455 -0.45 0.473-0.474 -0.37 23 0.338-0.339 0.08 0.357~0.358 -0.18 140 0.455-0.456 -0.5 0.474-0.475 -0.36 24 0.339-0.34 0.1 0.358-0.359 -0.14 141 0.456-0.457 -0.47 0.475-0.476 -0.31 25 0.34-0.341 0.15 0.359-0.36 -0.09 142 0.457~0.458 -0.49 0.476-0.477 -0.41 26 0.341-0.342 0.12 0.36-0.361 -0.15 143 0.458-0.459 -0.47 0.477~0.478 -0.41 27 0.342-0.343 0.11 0.361-0.362 -0.13 144 0.459-0.46 -0.52 0.478-0.479 -0.41 28 0.343-0.344 0.06 0.362-0.363 -0.13 145 0.46-0.461 -0.58 0.479-0.48 -0.36 29 0.344-0.345 0.17 0.363-0.364 -0.09 146 0.461-0.462 -0.61 0.48-0.481 -0.44 30 0.345-0.346 0.09 0.364-0.365 -0.13 147 0.462-0.463 -0.64 0.481-0.482 -0.37 31 0.346-0.347 0.14 0.365-0.366 -0.08 148 0.463-0.464 -0.55 0.482-0.483 -0.38 32 0.347~0.348 0.08 0.366-0.367 -0.06 149 0.464-0.465 -0.57 0.483-0.484 -0.46 33 0.348-0.349 0.11 0.367~0.368 -0.06 150 0.465-0.466 -0.68 0.484-0.485 -0.52 34 0.349-0.35 0.13 0.368-0.369 -0.08 151 0.466-0.467 -0.57 0.485-0.486 -0.57 35 0.35-0.351 0.08 0.369-0.37 -0.06 152 0.467~0.468 -0.78 0.486-0.487 -0.47 36 0.351-0.352 0.14 0.37~0.371 -0.09 153 0.468-0.469 -0.75 0.487~0.488 -0.55 37 0.352-0.353 0.13 0.371-0.372 -0.03 154 0.469-0.47 -0.64 0.488-0.489 -0.45 38 0.353-0.354 0.12 0.372-0.373 -0.01 155 0.47~0.471 -0.74 0.489-0.49 -0.74 39 0.354-0.355 0.13 0.373-0.374 -0.03 156 0.471-0.472 -0.57 0.49-0.491 -0.52 40 0.355-0.356 0.12 0.374-0.375 -0.06 157 0.472-0.473 -0.69 0.491-0.492 -0.59 41 0.356-0.357 0.15 0.375-0.376 -0.04 158 0.473-0.474 -0.73 0.492-0.493 -0.57 42 0.357~0.358 0.14 0.376-0.377 -0.04 159 0.474-0.475 -0.74 0.493-0.494 -0.59 43 0.358-0.359 0.16 0.377~0.378 -0.01 160 0.475-0.476 -0.84 0.494-0.495 -0.54 44 0.359-0.36 0.14 0.378-0.379 -0.01 161 0.476-0.477 -0.79 0.495-0.496 -0.63 45 0.36-0.361 0.14 0.379-0.38 0 162 0.477~0.478 -0.81 0.496-0.497 -0.69 46 0.361-0.362 0.14 0.38-0.381 -0.01 163 0.478-0.479 -0.78 0.497~0.498 -0.63 47 0.362-0.363 0.15 0.381-0.382 0.03 164 0.479-0.48 -0.71 0.498-0.499 -0.7 48 0.363-0.364 0.09 0.382-0.383 0 165 0.48-0.481 -0.94 0.499-0.5 -0.69 49 0.364-0.365 0.1 0.383-0.384 0.01 166 0.481-0.482 -0.8 0.5-0.501 -0.64 50 0.365-0.366 0.14 0.384-0.385 0 167 0.482-0.483 -0.74 0.501-0.502 -0.75 28 51 0.366-0.367 0.12 0.385-0.386 0.04 168 0.483-0.484 -0.78 0.502-0.503 -0.71 52 0.367~0.368 0.11 0.386-0.387 0.03 169 0.484-0.485 -0.95 0.503-0.504 -0.85 53 0.368-0.369 0.12 0.387~0.388 0.03 170 0.485-0.486 -0.81 0.504-0.505 -0.67 54 0.369-0.37 0.15 0.388-0.389 0.04 171 0.486-0.487 -0.96 0.505-0.506 -0.97 55 0.37~0.371 0.15 0.389-0.39 0.03 172 0.487~0.488 -1 0.506-0.507 -0.81 56 0.371-0.372 0.14 0.39-0.391 0.05 173 0.488-0.489 -0.91 0.507~0.508 -0.72 57 0.372-0.373 0.09 0.391-0.392 0.02 174 0.489-0.49 -0.86 0.508-0.509 -0.75 58 0.373-0.374 0.11 0.392-0.393 0.03 175 0.49-0.491 -0.85 0.509-0.51 -0.6 59 0.374-0.375 0.13 0.393-0.394 0.05 176 0.491-0.492 -1.01 0.51-0.511 -0.78 60 0.375-0.376 0.11 0.394-0.395 0.07 177 0.492-0.493 -1.11 0.511-0.512 -0.76 61 0.376-0.377 0.12 0.395-0.396 0.05 178 0.493-0.494 -0.94 0.512-0.513 -0.75 62 0.377~0.378 0.13 0.396-0.397 0.07 179 0.494-0.495 -1.01 0.513-0.514 -0.82 63 0.378-0.379 0.08 0.397~0.398 0.06 180 0.495-0.496 -0.95 0.514-0.515 -0.75 64 0.379-0.38 0.13 0.398-0.399 0.03 181 0.496-0.497 -0.99 0.515-0.516 -1.15 65 0.38-0.381 0.08 0.399-0.4 0.08 182 0.497~0.498 -1.09 0.516-0.517 -0.68 66 0.381-0.382 0.06 0.4-0.401 0.08 183 0.498-0.499 -1.17 0.517~0.518 -0.73 67 0.382-0.383 0.12 0.401-0.402 0.1 184 0.499-0.5 -0.96 0.518-0.519 -1.07 68 0.383-0.384 0.1 0.402-0.403 0.09 185 0.5-0.501 -1.02 0.519-0.52 -1 69 0.384-0.385 0.11 0.403-0.404 0.08 186 0.501-0.502 -1.06 0.52-0.521 -0.93 70 0.385-0.386 0.08 0.404-0.405 0.09 187 0.502-0.503 -1.13 0.521-0.522 -0.99 71 0.386-0.387 0.07 0.405-0.406 0.09 188 0.503-0.504 -1.48 0.522-0.523 -1 72 0.387~0.388 0.07 0.406-0.407 0.1 189 0.504-0.505 -1.16 0.523-0.524 -1.01 73 0.388-0.389 0.07 0.407~0.408 0.06 190 0.505-0.506 -0.8 0.524-0.525 -1.17 74 0.389-0.39 0.07 0.408-0.409 0.07 191 0.506-0.507 -1.22 0.525-0.526 -1.13 75 0.39-0.391 0.1 0.409-0.41 0.08 192 0.507~0.508 -1.06 0.526-0.527 -1.14 76 0.391-0.392 0.06 0.41-0.411 0.06 193 0.508-0.509 -1.31 0.527~0.528 -0.73 77 0.392-0.393 0.06 0.411-0.412 0.05 194 0.509-0.51 -1.27 0.528-0.529 -1.01 78 0.393-0.394 0.06 0.412-0.413 0.09 195 0.51-0.511 -1.05 0.529-0.53 -1.15 79 0.394-0.395 0.05 0.413-0.414 0.06 196 0.511-0.512 -1.37 0.53-0.531 -1.03 80 0.395-0.396 0.04 0.414-0.415 0.08 197 0.512-0.513 -1.39 0.531-0.532 -1.06 81 0.396-0.397 0.06 0.415-0.416 0.05 198 0.513-0.514 -1.43 0.532-0.533 -1.05 29 82 0.397~0.398 0.03 0.416-0.417 0.04 199 0.514-0.515 -1.45 0.533-0.534 -1.42 83 0.398-0.399 0.02 0.417~0.418 0.09 200 0.515-0.516 -1.3 0.534-0.535 -0.89 84 0.399-0.4 0.09 0.418-0.419 0.06 201 0.516-0.517 -1.38 0.535-0.536 -1.8 85 0.4-0.401 0.02 0.419-0.42 -0.01 202 0.517~0.518 -0.94 0.536-0.537 -0.81 86 0.401-0.402 0.01 0.42-0.421 0.09 203 0.518-0.519 -1.48 0.537~0.538 -0.89 87 0.402-0.403 0.03 0.421-0.422 0.08 204 0.519-0.52 -1.48 0.538-0.539 -0.91 88 0.403-0.404 0 0.422-0.423 0.06 205 0.52-0.521 -0.91 0.539-0.54 -0.96 89 0.404-0.405 0.03 0.423-0.424 0.08 206 0.521-0.522 -0.89 0.54-0.541 -1.98 90 0.405-0.406 0.02 0.424-0.425 0.03 207 0.522-0.523 -1.9 0.541-0.542 -0.29 91 0.406-0.407 0.03 0.425-0.426 0.06 208 0.523-0.524 -1.46 0.542-0.543 -1.28 92 0.407~0.408 0.02 0.426-0.427 0.05 209 0.524-0.525 -2.02 0.543-0.544 -1.84 93 0.408-0.409 -0.01 0.427~0.428 0.06 210 0.525-0.526 -1.39 0.544-0.545 -1.41 94 0.409-0.41 -0.06 0.428-0.429 0.03 211 0.526-0.527 -1.72 0.545-0.546 -0.54 95 0.41-0.411 -0.06 0.429-0.43 0.04 212 0.528-0.529 -1.08 0.547~0.548 -1.31 96 0.411-0.412 -0.04 0.43-0.431 0.05 213 0.529-0.53 -1.42 0.548-0.549 -1.11 97 0.412-0.413 -0.04 0.431-0.432 0.01 214 0.53-0.531 -1.71 0.549-0.55 -1.38 98 0.413-0.414 -0.02 0.432-0.433 0.04 215 0.531-0.532 -2.27 0.55-0.551 -1.5 99 0.414-0.415 -0.05 0.433-0.434 0 216 0.532-0.533 -1.78 0.551-0.552 -1.22 100 0.415-0.416 -0.07 0.434-0.435 -0.02 217 0.533-0.534 -1.55 0.552-0.553 -0.8 101 0.416-0.417 -0.08 0.435-0.436 0.01 218 0.535-0.536 -1.25 0.553-0.554 -1.32 102 0.417~0.418 -0.11 0.436-0.437 0.04 219 0.536-0.537 -1.09 0.554-0.555 -1.79 103 0.418-0.419 -0.07 0.437~0.438 0.01 220 0.537~0.538 -2.02 0.556-0.557 -1.3 104 0.419-0.42 -0.09 0.438-0.439 -0.01 221 0.54-0.541 -2.16 0.557~0.558 -1.48 105 0.42-0.421 -0.13 0.439-0.44 -0.01 222 0.541-0.542 -1.64 0.558-0.559 -1.7 106 0.421-0.422 -0.1 0.44-0.441 -0.01 223 0.544-0.545 -2.3 0.559-0.56 -1.55 107 0.422-0.423 -0.12 0.441-0.442 -0.01 224 0.546-0.547 -2.51 0.561-0.562 -1.62 108 0.423-0.424 -0.11 0.442-0.443 -0.06 225 0.548-0.549 -2.7 0.563-0.564 -1.68 109 0.424-0.425 -0.17 0.443-0.444 -0.04 226 0.549-0.55 -1.77 0.564-0.565 -1.47 110 0.425-0.426 -0.14 0.444-0.445 -0.07 227 0.55-0.551 -1.08 0.569-0.57 -1.42 111 0.426-0.427 -0.14 0.445-0.446 -0.11 228 0.551-0.552 -2.13 0.58-0.581 -1.74 112 0.427~0.428 -0.15 0.446-0.447 -0.13 229 0.553-0.554 -2.19 0.583-0.584 -2.43 30 113 0.428-0.429 -0.19 0.447~0.448 -0.08 230 0.555-0.556 -2.04 0.6-0.601 -1.79 114 0.429-0.43 -0.18 0.448-0.449 -0.11 231 0.556-0.557 -1.93 115 0.43-0.431 -0.18 0.449-0.45 -0.07 232 0.562-0.563 -2.51 116 0.431-0.432 -0.21 0.45-0.451 -0.16 233 0.572-0.573 -1.85 117 0.432-0.433 -0.26 0.451-0.452 -0.08 234 0.574-0.575 -2.74 c) Window combination determining breakpoint, for each site in the reference genome sequence, 100 windows located at either side of the site were selected respectively from two sides of the site as two populations for Run-Test, one p value corresponding to each site was 5 obtained by calculating difference between two sides of the site, 3000 sites having the minimum p value as breakpoint. screening breakpoint: all arranged breakpoints were recorded as B 1 {b 1 ,b 2 .
b,} each breakpoint presented between two successive fragments, in which such two fragments were regions respective from a previous breakpoint to said breakpoint and 10 from said breakpoint to the a next breakpoint, all zij in such two fragments were subjected to Run-Test. The obtained p value (Pk) was regarded as "bk was taken as significance of breakpoint". A candidate breakpoint having the maximum p value Pk was removed, which were repeated until all p value smaller than the final p value Pfi-I of such chromosome being as 1.1X1 . 15 d) after the breakpoints were screened out, a region between two successive breakpoints was determined as a detection window, for window combination. To further filter fragments obtained by window combination, a mean value of zij in such fragment was calculated, which was recorded as Z. If Z exceeded a threshold, then copy number variation was determined presenting in such fragment. -1.645 was used as the 20 first threshold, and 1.645 was used as the second threshold. 4. Result Table.2 showed a detection result list of copy number variation after whole genome amplifying the embryo single cell sample in current example. Table.2 Detection result list of copy number variation after whole genome amplifying the 25 embryo single cell sample in current example 31 starting terminating size of type of No. chromosome point of Involved region NV point of CNV CNV CNV CNV 5 63,429 23,496,649 23.4M deletion 4q34.3--q35.2 Si 12 16,037 18,926,068 18.9M repeat 7p21.1--p22.3 S2 21 1 46,944,323 46.9M repeat 21p13--q22.3 It could be seen from Table.2 that using the method of detemining whether copy number variation presents in a genome sample according to embodiments of the present disclosure, various types of copy number variation could be effectively determined. 5 Example 2 Using the embryo single cell sample same as that in Example 1, all steps were rereated as Example 1 except the genome DNA was directly subjected to sequencing (without firstly subjected to whole genome amplification). Comparision result between 10 Example 1 and Example 2 was shown in Table 3, Fig.4 and Fig.5. Table 3. Comparision result of detecting copy number variation of reads obtained by subjected each genome sample to whole genome amplification and not to whole genome amplification sequencing result of sequencing result of embryo single cell No. chromosome embryo single cell genome DNA by the determining genome DNA (without method of the present result subjected to WGA) disclosure deletion: Deletion: S1 5 consistent 10,002-23,312,155 63,429-23,496,649 32 repeat: repeat: 12 consistent 145,741-14,780,155 16,037-18,926,068 S2 21 21 trisomy 21 trisomy consistent It could be seen from data in Table.3 and images of chromosome karyotype in Fig.4 and Fig.5 that the detection results of reads copy number variation between the genome DNA sample which was subjected to whole genome amplificaiton and the genome DNA sample which was not subjected to whole genome amplificaiton were consistent. For 5 difference of staring and terminating points of "deletion" or "repeat" in Table.3, as the boundary of copy number variation was hard to be accurately determined, in general for the primary window having a length of about 150K, two boundaries having difference within a range of 100 to 300 Kb could be determined as being fully consistent, two boundaries having difference within a range of 300Kb to 1 Mb could be determined as 10 being quite consistent. Since the difference between bondaries of copy number variation determined by the two methods in Table 3. was within the range of 100 to 300 Kb or within the range of 300Kb to 1 Mb, it could determine that the boundaries of copy number variation determined by the two methods were consistent. 15 Industrial applicability The method, system and computer readable medium of determining whether copy number variation presents in a genome sample of the present disclosure may be effectively used to determine whether copy number variation presents in a genome sample. 20 Reference throughout this specification to "an embodiment," "some embodiments," 33 "one embodiment", "another example," "an example," "a specific examples" or "some examples," means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present disclosure. Thus, the appearances of the phrases 5 such as "in some embodiments," "in one embodiment", "in an embodiment", "in another example, "in an example," "in a specific examples," or "in some examples," in various places throughout this specification are not necessarily referring to the same embodiment or example of the present disclosure. Furthermore, the particular features, structures, materials, or characteristics may be combined in any suitable manner in one 10 or more embodiments or examples. Although explanatory embodiments have been shown and described, it would be appreciated by those skilled in the art that the above embodiments cannot be construed to limit the present disclosure, and changes, alternatives, and modifications can be made in the embodiments without departing from spirit, principles and scope of the present 15 disclosure. 34

权利要求:
Claims (48)
[1] 1. A method of determining whether copy number variation presents in a genome sample, comprising following steps: 5 sequencing the genome sample, to obtain a sequencing result consisting of a plurality of reads; aligning the sequencing result to a reference genome sequence, to determine a distribution of the reads in the reference genome sequence; determining a plurality of breakpoints in the reference genome sequence based on 10 the distribution of the reads in the reference genome sequence, wherein the number of reads has significance at both sides of the breakpoints; determining a detection window in the reference genome based on the plurality of the breakpoints; determining a first parameter based on reads falling in the detection window; and 15 determining whether the copy number variation presents in the genome sample against the detection window based on difference between the first parameter and a preset threshold.
[2] 2. The method of claim 1, further comprising a step of extracting the genome sample 20 from a biological sample.
[3] 3. The method of claim 2, wherein the biological sample is pregnant sample or fetal sample, optionally, the biological sample is at least one selected from a group consisting of 25 pregnant plasma, chorionic villi, amniotic fluid, umbilical cord blood, placenta and fetal heel blood.
[4] 4. The method of claim 2, wherein the biological sample is at least one selected from a group consisting of blood, urine, saliva, tissue, germ cells, oosperm, blastomere and 30 embryo, optionally, the biological sample is a single cell. 35
[5] 5. The method of claim 1, wherein the step of sequencing the genome sample further comprises following sub-steps of: amplifying the genome sample; constructing a sequencing-library with amplified genome sample; and 5 sequencing the sequencing-library.
[6] 6. The method of claim 4, further comprising a step of: lysing the single cell, to release whole genome of the single cell. 10
[7] 7. The method of claim 6, wherein the single cell is lysed using an alkaline lysate, to release whole genome of the single cell.
[8] 8. The method of claim 7, wherein the whole genome is amplified by means of PCR-based whole genome amplification method. 15
[9] 9. The method of claim 8, wherein the PCR-based whole genome amplification method is OmniPlex WGA.
[10] 10. The method of claim 5, wherein the sub-step of sequencing the 20 sequencing-library is performed by at least one selected from a group consisting of Hiseq system, Miseq system, Genome Analyzer system, 454 FLX, SOLiD system, Ion Torrent system and single molecule sequencing apparatus.
[11] 11. The method of claim 1, wherein the copy number variation is at least one 25 selected from aneuploidy of chromosome, deletion of chromosome, and addition micro-deletion and micro-repetition of chromosome fragments.
[12] 12. The method of claim 1, wherein the step of determining a plurality of breakpoints in the reference genome sequence further comprises following sub-steps: 30 dividing the reference genome sequence into a plurality of primary windows having a predetermined length, and determining reads falling in each of the plurality of the primary windows; 36 for at least one site in the reference genome sequence, determining the number of reads falling in the same number of the plurality of primary windows at both sides of the site; determining p value of the site, wherein the p value represents that the number of 5 reads falling in either side of the site has significance; and determining that the site is the breakpoints, if the p value of the site is smaller than a final p value.
[13] 13. The method of claim 12, wherein the reads falling in each of the plurality of 10 primary windows are uniquely-aligned reads.
[14] 14. The method of claim 12, wherein 100 of primary windows are selected from either side of the site.
[15] 15 15. The method of claim 12, wherein the plurality of primary windows have a length of 100 Kbp to 200 Kbp, preferably 150 Kbp.
[16] 16. The method of claim 12, wherein the final p value is 1.1 X 105 or less. 20
[17] 17. The method of claim 12, wherein the sub-step of determining p value of the site further comprises: for the site, selecting the plurality of primary windows having the same number at either side of the site respectively, and calculating the relative number of reads falling in each of the plurality of primary windows Ri, wherein i represents No. of the plurality of 25 primary windows, subjecting all of the relative numbers of reads falling in the plurality of primary windows Ri to Run-Test, to determine the p value of the site, wherein the relative number of reads is determined by following formula: .R log, 30 wherein ri represents the number of reads falling in the i-th primary window, 37 - = -S r, na n represents the total number of the plurality of primary windows.
[18] 18. The method of claim 17, wherein subjecting all of the relative numbers of the 5 reads falling in each of the plurality of primary windows to Run-Test further comprises: subjecting the relative number of reads falling in each of the plurality of primary windows Ri to a correction of GC content, to obtain corrected relative number of reads RC. determining the normalized number of reads falling in each of the plurality of primary 10 windows Zi based on the corrected relative number of reads; and subjecting all of the normalized numbers of reads falling in each of the plurality of primary windows Zi to Run-Test.
[19] 19. The method of claim 18, wherein the corrected relative number of reads i is 15 obtained by following steps: calculating GC content of each of the plurality of primary windows; dividing the GC content into a plurality of regions in a unit of 0.001, and calculating a mean value Ms among all of the relative numbers of reads falling in each of the plurality of regions, wherein s is No. of the plurality of regions; 20 determining the corrected relative number of reads i based on the following formula: f( =R( -Ml, determining the normalized number of reads Zi based on the following formula: wherein 25 Z, ={.R, -4 SD 1 n mean = - (R -aN SI) N:(. R .38 38
[20] 20. The method of claim 19, wherein the step of determining a detection window in the reference genome based on the plurality of the breakpoints further comprises: 1) determining a plurality of candidate breakpoints, wherein other breakpoints 5 present both before and after the candidate breakpoints; 2) determining p value of each candidate breakpoint, and removing a candidate breakpoint having the maximal p value; 3) performing the step 2) with rest of the candidate breakpoints until all p values of the rest of the candidate breakpoints are smaller than the final p value, wherein the rest 10 of the candidate breakpoints are taken as screened candidate breakpoints; and 4) determining a region between two successive screened candidate breakpoints as the detection window, wherein the p value of the candidate breakpoint is obtained by following steps: selecting a region between the candidate breakpoint and previous candidate 15 breakpoint as a first candidate region, and selecting a region between the candidate breakpoint and next candidate breakpoint as a second candidate region; subjecting the normalized number of reads falling in the primary windows Zi which are included both in the first candidate region and the second candidate region to Run-Test, to determine the p value of the candidate breakpoints, 20 optionally, the final p value is obtained by following steps: based on a sequencing result of a control sample, repeating the step of determining a detection window in the reference genome, and recording p values of the breakpoints which are removed each time until the number of the breakpoints is zero; and determining the final p value, based on p values of removed breakpoints, 25 optionally, the final p value is 1.1 X 10-5.
[21] 21. The method of claim 20, wherein the step of determining a first parameter based on the reads falling in the detection window further comprises: determining a mean value among all of the normalized numbers of reads falling in 30 each of the plurality of primary windows Z which are included in the detection windows, wherein the mean value of the normalized numbers of reads Z is taken as the first 39 parameter.
[22] 22. The method of claim 1, wherein the preset threshold comprises: a first threshold being -1.645 and a second threshold being 1.645. 5
[23] 23. The method of claim 1, wherein the reference genome sequence is at least one selected from human chromosome 21, chromosome 18, chromosome 13, chromosome X and chromosome Y. 10
[24] 24. A system for determining whether copy number variation presents in a genome sample, comprising: a sequencing apparatus, configured to sequence the genome sample, to obtain a sequencing result consisting of a plurality of reads; an analysis apparatus, connected to the sequencing apparatus, configured to 15 determine whether copy number variation presents in the genome sample based on the sequencing result, wherein the analysis apparatus further comprises: an aligning unit, configured to align the sequencing result to a reference genome sequence, to determine a distribution of the reads in the reference genome sequence; 20 a breakpoint determining unit, connected to the aligning unit, configured to determine a plurality of breakpoints in the reference genome sequence based on the distribution of the reads in the reference genome sequence, wherein the number of reads has significance between two sides of the breakpoints; a detection window determining unit, connected to the breakpoint determining 25 unit, configured to determine a detection window in the reference genome based on the plurality of the breakpoints; a parameter determining unit, connected to the detection window determining unit, configured to determine a first parameter based on reads falling in the detection window; and 30 a determining unit, connected to the parameter determining unit, configured to determine whether the copy number variation presents in the genome sample against the detection window based on difference between the first parameter and a preset 40 threshold.
[25] 25. The system of claim 24, further comprising a genome extracting apparatus, configured to extract the genome sample from a biological sample. 5
[26] 26. The system of claim 24, wherein the sequencing apparatus further comprises: a genome amplifying unit, configured to amplify the genome sample; a sequencing-library constructing unit, connected to the genome amplifying unit, configured to construct a sequencing-library with amplified genome sample; and 10 a sequencing unit, connected to the sequencing-library constructing unit, configured to sequence the sequencing-library.
[27] 27. The system of claim 26, wherein the sequencing unit is at least one selected from a group consisting of Hiseq system, Miseq system, Genome Analyzer system, 454 15 FLX, SOLiD system, Ion Torrent system and single molecule sequencing apparatus.
[28] 28. The system of claim 24, wherein the breakpoint determining unit further comprises a module for performing following sub-steps: dividing the reference genome sequence into a plurality of primary windows having a 20 predetermined length, and determining reads falling in each of the plurality of the primary windows; for at least one site in the reference genome sequence, determining the number of reads falling in the same number of the plurality of primary windows at both sides of the site; 25 determining p value of the site, wherein the p value represents that the number of reads falling in either side of the site has significance; and determining the site is the breakpoints, if the p value of the site is smaller than a final p value. 30
[29] 29. The system of claim 28, wherein the breakpoint determining unit further comprises a module for performing followings to determine the p value: for the site, selecting the plurality of primary windows having the same number at 41 either side of the site respectively, and calculating the relative number of reads falling in each of the plurality of primary windows Ri, wherein i represents No. of the plurality of primary windows, subjecting all of the relative numbers of reads falling in the plurality of primary 5 windows Ri to Run-Test, to determine the p value of the site, wherein the relative number of reads is determined by following formula: .R log, wherein r represents the number of reads falling in the i-th primary window, 10 n represents the total number of the plurality of primary windows.
[30] 30. The system of claim 29, wherein the breakpoint determining unit further comprises a module for performing followings to subject all of the relative numbers of the reads falling in the plurality of primary windows to Run-Test: 15 subjecting the relative number of reads falling in each of the plurality of primary windows Ri to a correction of GC content, to obtain corrected relative number of reads RC. determining the normalized number of reads falling in each of the plurality of primary windows Zi based on the corrected relative number of reads; and 20 subjecting all of the normalized numbers of reads falling in each of the plurality of primary windows Zi to Run-Test.
[31] 31. The system of claim 30, wherein the corrected relative number of reads £ is obtained by a module for performing following steps: 25 calculating GC content of each of the plurality of primary windows; dividing the GC content into a plurality of regions in a unit of 0.001, and calculating a mean value Ms among all of the relative numbers of reads falling in each of the plurality of regions, wherein s is No. of the plurality of regions; determining the corrected relative number of reads i based on the following 42 formula: [{=R -M. determining the normalized number of reads Zi based on the following formula: wherein 5 Zp ={ -' -a ,wherein meRn R i
[32] 32. The system of claim 31, wherein based on the plurality of the breakpoints, the 10 detection window determining unit further comprises a module for performing followings: 1) determining a plurality of candidate breakpoints, wherein other breakpoints present both before and after the candidate breakpoints; 2) determining p value of each candidate breakpoint, and removing a candidate breakpoint having the maximal p value; 15 3) performing the step 2) with rest of the candidate breakpoints until all p values of the rest of the candidate breakpoints are smaller than the final p value, wherein the rest of the candidate breakpoints are taken as screened candidate breakpoints; and 4) determining a region between two successive screened candidate breakpoints as the detection window, 20 wherein the p value of the candidate breakpoint is obtained by following steps: selecting a region between the candidate breakpoint and previous candidate breakpoint as a first candidate region, and selecting a region between the candidate breakpoint and next candidate breakpoint as a second candidate region; subjecting the normalized number of reads falling in the primary windows Zi which 25 are included both in the first candidate region and the second candidate region to Run-Test, to determine the p value of the candidate breakpoints, optionally, the final p value is obtained by following steps: based on a sequencing result of a control sample, repeating the step of determining a detection window in the reference genome, and recording p values of the breakpoints 43 which are removed each time until the number of the breakpoints is zero; and determining the final p value, based on a distribution of the p values of removed breakpoints, optionally, the final p value is 1.1 X 10 . 5
[33] 33. The system of claim 32, wherein the parameter determining unit further comprises a module for performing followings: determining a mean value among all of the normalized numbers of reads falling in each of the plurality of primary windows Z which are included in the detection windows, 10 wherein the mean value of the normalized numbers of reads Z is taken as the first parameter.
[34] 34. The system of the claim 24, wherein a preset threshold is preserved in the determining unit, wherein the preset threshold comprises: a first threshold being -1.645 15 and a second threshold being 1.645.
[35] 35. The system of claim 24, wherein the reference genome sequence is preserved in the aligning unit, wherein the reference genome sequence is known human genome sequence, optionally, the reference genome sequence is at least one selected from 20 human chromosome 21, chromosome 18, chromosome 13, chromosome X and chromosome Y.
[36] 36. A computer readable medium, comprising an order, configured to perform by a processer to determine whether copy number variation presents in a genome sample 25 through following steps: aligning the sequencing result to a reference genome sequence, to determine a distribution of the reads in the reference genome sequence; determining a plurality of breakpoints in the reference genome sequence based on the distribution of the reads in the reference genome sequence, wherein the number of 30 reads has significance at both sides of the breakpoints; determining a detection window in the reference genome based on the plurality of 44 the breakpoints; determining a first parameter based on reads falling in the detection window; and determining whether the copy number variation presents in the genome sample against the detection window based on difference between the first parameter and a 5 preset threshold.
[37] 37. The computer readable medium of claim 36, wherein the step of determining a plurality of breakpoints in the reference genome sequence further comprises following sub-steps: 10 dividing the reference genome sequence into a plurality of primary windows having a predetermined length, and determining reads falling in each of the plurality of the primary windows; for at least one site in the reference genome sequence, determining the number of reads falling in the same number of the plurality of primary windows at both sides of the 15 site; determining p value of the site, wherein the p value represents that the number of reads falling in either side of the site has significance; and determining the site is the breakpoints, if the p value of the site is smaller than a final p value. 20
[38] 38. The computer readable medium of claim 37, wherein the reads falling in each of plurality of the primary windows are uniquely-aligned reads.
[39] 39. The computer readable medium of claim 37, wherein 100 of primary windows are 25 selected from either side of the site.
[40] 40. The computer readable medium of claim 37, wherein the plurality of primary windows have a length of 100 Kbp to 200 Kbp, preferably 150 Kbp. 30
[41] 41. The computer readable medium of claim 37, wherein the final p value is 1.1 X 10-5 or less. 45
[42] 42. The computer readable medium of claim 37, wherein the sub-step of determining p value of the site further comprises: for the site, selecting the plurality of primary windows having the same number at at both sides of the site respectively, and calculating the relative number of reads falling in 5 each of the plurality of primary windows Ri, wherein i represents No. of the plurality of primary windows, subjecting all of the relative numbers of reads falling in the plurality of primary windows Ri to Run-Test, to determine the p value of the site, wherein the relative number of reads is determined by following formula: R, =loag 10 wherein r represents the number of reads falling in the i-th primary window, n represents the total number of the plurality of primary windows. 15
[43] 43. The computer readable medium of claim 42, wherein subjecting the all of the relative numbers of the reads falling in the plurality of primary windows to Run-Test further comprises: subjecting the relative number of reads falling in each of the plurality of primary windows Ri to a correction of GC content, to obtain corrected relative number of reads 20 ; determining the normalized number of reads falling in each of the plurality of primary windows Zi based on the corrected relative number of reads; and subjecting all of the normalized number of reads falling in each of the plurality of primary windows Zi to Run-Test. 25
[44] 44. The computer readable medium of claim 43, wherein the corrected relative number of reads is obtained by following steps: calculating GC content of each of the plurality of primary windows; dividing the GC content into a plurality of regions in a unit of 0.001, and calculating a 46 mean value Ms among all of the relative numbers of reads falling in each of the plurality of regions, wherein s is No. of the plurality of regions; determining the corrected relative number of reads based on the following formula: 5 1I{ = R m determining the normalized number of reads Zi based on the following formula: wherein Z, ={R -R -mean ,wherein mean R ' SD :- -J(R - -ine 10
[45] 45. The computer readable medium of claim 43, wherein based on the plurality of the breakpoints, the step of determining a detection window in the reference genome further comprises: 15 1) determining a plurality of candidate breakpoints, wherein other breakpoints present both before and after the candidate breakpoints; 2) determining p value of each candidate breakpoint, and removing a candidate breakpoint having the maximal p value; 3) performing the step 2) with rest of the candidate breakpoints until all p values of 20 the rest of the candidate breakpoints are smaller than the final p value, wherein the rest of the candidate breakpoints are taken as screened candidate breakpoints; and 4) determining a region between two successive screened candidate breakpoints as the detection window, wherein the p value of the candidate breakpoint is obtained by following steps: 25 selecting a region between the candidate breakpoint and previous candidate breakpoint as a first candidate region, and selecting a region between the candidate breakpoint and next candidate breakpoint as a second candidate region; subjecting the normalized number of reads falling in the primary windows Zi which are included both in the first candidate region and the second candidate region to 47 Run-Test, to determine the p value of the candidate breakpoints, optionally, the final p value is obtained by following steps: based on a sequencing result of a control sample, repeating the step of determining a detection window in the reference genome, and recording p values of the breakpoints 5 which are removed each time until the number of the breakpoints is zero; and determining the final p value, based on p values of removed breakpoints, optionally, the final p value is 1.1 X 10 .
[46] 46. The computer readable medium of claim 45, wherein based on the reads falling 10 in the detection window, the step of determining a first parameter further comprises: determining a mean value among all of the normalized numbers of reads falling in all each of the plurality of primary windows Z which are included in the detection windows, wherein the mean value of the normalized numbers of reads Z is taken as the first parameter. 15
[47] 47. The computer readable medium of claim 46, wherein the preset threshold comprises: a first threshold being -1.645 and a second threshold being 1.645.
[48] 48. The computer readable medium of claim 36, wherein the reference genome 20 sequence is at least one selected from human chromosome 21, chromosome 18, chromosome 13, chromosome X and chromosome Y. 48

类似技术:

---

公开号 | 公开日 | 专利标题

---

AU2012366077B2|2016-01-21|Method and system for determining whether copy number variation exists in sample genome, and computer readable medium

---

MX2007001183A|2009-02-05|Stator blade airfoil profile for a compressor.

---

CN101169122A|2008-04-30|Airfoil shape for a compressor

---

CN101173687A|2008-05-07|Airfoil shape for a compressor

---

CN101169128A|2008-04-30|Airfoil shape for a compressor

---

CN101169133A|2008-04-30|Airfoil shape for a compressor

---

CN101173688A|2008-05-07|Airfoil shape for a compressor

---

CN101169127A|2008-04-30|Airfoil shape for a compressor

---

Edvardsson et al.2003|A search for H/ACA snoRNAs in yeast using MFE secondary structure prediction

---

Mahalanobis et al.1934|Tables of random samples from a normal population

---

Walker2016|Confidence intervals for Kendall’s tau with small samples

---

CA2721313A1|2009-10-15|Method and apparatus for determining a probability of colorectal cancer in a subject

---

Guertin et al.2018|Health utilities index mark 3 scores for major chronic conditions: population norms for Canada based on the 2013-2014 Canadian Community Health Survey

---

Carroll et al.1987|Local and non-local spin density functional calculations of the correlation energy of atoms in molecules

---

Xiong et al.2015|Lineage divergence in Odorrana graminea complex |

---

Coughlin et al.2000|Exchange rate pass-through in US manufacturing: exchange rate index choice and asymmetry issues

---

WO2019213810A1|2019-11-14|Method, apparatus, and system for detecting chromosome aneuploidy

---

WO2019213811A1|2019-11-14|Method, apparatus, and system for detecting chromosomal aneuploidy

---

Shin et al.2016|Evaluation of weather information for electricity demand forecasting

---

Park et al.2015|Real variance estimation of BEAVRS benchmark in McCARD Monte Carlo eigenvalue calculations

---

Meshkat et al.2018|Point prediction for the proportional hazards family based on progressive Type-II censoring with binomial removals

---

Abad et al.2022|An exponential analysis of total factor productivity

---

Gao et al.2022|The Effect of China's Regional Economic Competitiveness on CO2 Emissions-Based on Economic Factors

---

Ah-Cann2019|Screening for breath: identifying Aurkb as a novel regulator of lung development

---

Wang2015|Research on Technology Spillover Effects on Agricultural Productivity in China

同族专利:

---

公开号 | 公开日

---

RU2014134175A|2016-03-20|

---

EP2826865B1|2017-06-21|

---

SG11201404079SA|2014-10-30|

---

EP2826865A1|2015-01-21|

---

EP2826865B8|2017-08-16|

---

JP2015506684A|2015-03-05|

---

HK1215454A1|2016-08-26|

---

IL233691D0|2014-09-30|

---

CN105392894B|2018-05-29|

---

IL233691A|2019-01-31|

---

AU2012366077B2|2016-01-21|

---

EP2826865A4|2015-05-27|

---

KR101770884B1|2017-09-05|

---

KR20140114442A|2014-09-26|

---

WO2013107048A1|2013-07-25|

---

JP5938484B2|2016-06-22|

---

RU2593708C2|2016-08-10|

---

CN105392894A|2016-03-09|

---

US20150012252A1|2015-01-08|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

US20030082606A1|2001-09-04|2003-05-01|Lebo Roger V.|Optimizing genome-wide mutation analysis of chromosomes and genes|

---

JP5491171B2|2006-04-12|2014-05-14|メディカルリサーチカウンシル|Method|

---

US7702468B2|2006-05-03|2010-04-20|Population Diagnostics, Inc.|Evaluating genetic disorders|

---

EP3751005A3|2008-09-20|2021-02-24|The Board of Trustees of the Leland Stanford Junior University|Noninvasive diagnosis of fetal aneuploidy by sequencing|

---

WO2011032040A1|2009-09-10|2011-03-17|Centrillion Technology Holding Corporation|Methods of targeted sequencing|

---

AU2011207544A1|2010-01-19|2012-09-06|Verinata Health, Inc.|Identification of polymorphic sequences in mixtures of genomic DNA by whole genome sequencing|

---

EP2591433A4|2010-07-06|2017-05-17|Life Technologies Corporation|Systems and methods to detect copy number variation|

---

EP2772549B8|2011-12-31|2019-09-11|BGI Genomics Co., Ltd.|Method for detecting genetic variation|CN107111692B|2014-10-10|2021-10-29|生命科技股份有限公司|Methods, systems, and computer-readable media for calculating corrected amplicon coverage|

---

WO2017161201A1|2016-03-16|2017-09-21|Cynvenio Biosystems Inc.|Cancer detection assay and related compositions, methods and systems|

---

CN108090325B|2016-11-23|2022-01-25|中国科学院昆明动物研究所|Method for analyzing single cell sequencing data by applying beta-stability|

---

CN109097457A|2017-06-20|2018-12-28|深圳华大智造科技有限公司|The method for determining predetermined site mutation type in sample of nucleic acid|

---

CN107590362B|2017-08-21|2019-12-06|武汉菲沙基因信息有限公司|Method for judging whether overlapping assembly is correct or incorrect based on long read sequence sequencing|

---

CN108251532B|2018-03-29|2021-12-28|上海锐翌生物科技有限公司|Fecal DNA colorectal tumor polygene prediction model based on NGS technology|

---

CN108573125A|2018-04-19|2018-09-25|上海亿康医学检验所有限公司|A kind of detection method of genome copies number variation and the device comprising this method|

---

CN112639129A|2018-09-03|2021-04-09|深圳华大智造科技有限公司|Method and apparatus for determining the genetic status of a new mutation in an embryo|

---

WO2021114139A1|2019-12-11|2021-06-17|深圳华大基因股份有限公司|Copy number variation detection method and device based on blood circulating tumor dna|

---

CN112562787B|2020-12-03|2021-09-07|江苏先声医学诊断有限公司|Gene large fragment rearrangement detection method based on NGS platform|

法律状态:
2016-05-19| FGA| Letters patent sealed or granted (standard patent)|

---

2017-04-13| HB| Alteration of name in register|Owner name: BGI GENOMICS CO., LTD Free format text: FORMER NAME(S): BGI DIAGNOSIS CO., LTD. |

优先权:

---

申请号 | 申请日 | 专利标题

---

PCT/CN2012/070680|WO2013107048A1|2012-01-20|2012-01-20|Method and system for determining whether copy number variation exists in sample genome, and computer readable medium|

---